Murrangatin may be a valuable anti-tumor-promoting agent, it can significantly inhibit Epstein-Barr virus early antigen (EBV-EA) activation, and preserve the high viability of Raji cells, it also exhibits cytotoxicity against cholangiocarcinoma cell line, KKU-100.

Bellidifolin shows the inhibition of monoamine oxidase activity.

Clivatuzumab is a humanized anti-myxinomab, which can target the MUC1 epitope highly expressed on the surface of most pancreatic cancer cells, and has a good therapeutic effect on a variety of tumor cells.